^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ASKC852
i
Other names: ASKC852, ASKC 852
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Aosaikang Pharma
Drug class:
TGF-β RI kinase inhibitor
Related drugs:
over3years
[VIRTUAL] A novel TGF-βRI inhibitor ASKC852, possessing antitumor and PD-L1 synergistic effect activities (AACR 2021)
Our data demonstrates ASK852 is a potent and highly selective TGF-βRI inhibitor. It effectively blocked the TGF-β-SMAD signal pathway, with anti-tumor effect in syngeneic mouse models. Pharmacokinetic profile and safety properties support ASKC852 as a potential anticancer agent for the clinical treatment of solid tumors.
PD(L)-1 Biomarker • IO biomarker
|
TGFB1 (Transforming Growth Factor Beta 1) • ITK (IL2 Inducible T Cell Kinase)
|
ASKC852
Share via
